… Immunotherapy is a promising approach to treating various types of cancers, including
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited effectiveness …

… or resistance of HCC to immunotherapies. In addition, current … emerging trials assessing
immunotherapies across all … yielding distinct responses to immunotherapy in HCCs induced …

… Major unmet challenges in HCC checkpoint immunotherapy … use of currently available
immunotherapies in HCC and the … evidence and clinical use of immunotherapy in HCC, with a …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …

… Blocking LAG-3 can augment T-cells activity, making it a potential immunotherapy target. …
LAG-3 may be a more effective target for immunotherapy than PD-1/PD-L1 or CTLA-4, as LAG-…

… -L1 (or PD-L2) on target cells this inhibits effector T cell responses. Therefore, blocking its
action is an attractive target of immunotherapy. Nivolumab’s grading as an approved second …

… targeting drug against angiogenesis, targeted drugs for HCC are continually emerging.
Moreover, immunotherapy … research progress of targeted therapy and immunotherapy for HCC in …

… of immunotherapies has been a major development in the treatment of many advanced cancers,
including hepatocellular carcinoma … Current limitations of immunotherapies and areas of …

… In this manuscript, we aimed to review the latest advances in the systemic treatment of
advanced hepatocellular carcinoma focusing on immunotherapy and targeted therapies. …

… : Immunotherapy is on the way to become the new standard of care for advanced hepatocellular
carcinoma (… -kinase inhibitors (TKIs) immunotherapeutics will probably replace sorafenib …